Manzano Miguel, Gabizón Alberto, Vallet-Regí María
Chemistry in Pharmaceutical Sciences, School of Pharmacy, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12, Plaza de Ramón y Cajal s/n, 28040 Madrid, Spain.
Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28034 Madrid, Spain.
Pharmaceutics. 2022 Jul 17;14(7):1483. doi: 10.3390/pharmaceutics14071483.
Nanomedicines have revolutionized the treatment of certain types of cancer, as is the case of doxil, liposomal formulation with doxorubicin encapsulated, in the treatment of certain types of ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma. These nanomedicines can improve the performance of conventional chemotherapeutic treatments, with fewer side effects and better efficiency against cancer. Although liposomes have been used in some formulations, different nanocarriers with better features in terms of stability and adsorption capabilities are being explored. Among the available nanoparticles in the field, mesoporous silica nanoparticles (MSNP) have attracted great attention as drug delivery platforms for the treatment of different diseases. Here, a novel formulation based on MSNP loaded with a potent antitumor prodrug that works in vitro as well as in a clinically evaluated liposomal formulation has been developed. This novel formulation shows excellent prodrug encapsulation efficiency and effective release of the anticancer drug only under certain stimuli typical of tumor environments. This behavior is of capital importance for translating this nanocarrier to the clinic in the near future.
纳米药物已经彻底改变了某些类型癌症的治疗方式，比如多柔比星脂质体（Doxil），一种包裹了阿霉素的脂质体制剂，用于治疗某些类型的卵巢癌、艾滋病相关的卡波西肉瘤和多发性骨髓瘤。这些纳米药物能够提高传统化疗的效果，副作用更少且抗癌效率更高。尽管脂质体已被用于一些制剂中，但人们正在探索在稳定性和吸附能力方面具有更好特性的不同纳米载体。在该领域现有的纳米颗粒中，介孔二氧化硅纳米颗粒（MSNP）作为治疗不同疾病的药物递送平台引起了极大关注。在此，已开发出一种基于负载强效抗肿瘤前药的MSNP的新型制剂，其在体外以及临床评估的脂质体制剂中均有效。这种新型制剂显示出优异的前药包封效率，并且仅在肿瘤环境特有的某些刺激下才有效释放抗癌药物。这种特性对于在不久的将来将这种纳米载体转化为临床应用至关重要。
